Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ducommun Inc
NYSE:DCO
|
US |
Prescient Therapeutics Ltd
Other Liabilities
Prescient Therapeutics Ltd
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Other Liabilities
AU$8.2k
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Liabilities
$13.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-19%
|
|
|
CSL Ltd
ASX:CSL
|
Other Liabilities
$973m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Other Liabilities
AU$41.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Liabilities
AU$23.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Liabilities
AU$354.5k
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Other Liabilities?
Other Liabilities
8.2k
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's Other Liabilities amounts to 8.2k AUD.
What is Prescient Therapeutics Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-18%
The average annual Other Liabilities growth rates for Prescient Therapeutics Ltd have been -46% over the past three years , -18% over the past five years .
